Concept
Antigen processing
Personnes associées (32)
Horst Vogel
Horst Vogel est né en 1948 à Würzburg, Allemagne. Après ses études en chimie, il obtient le diplôme de chimie en 1974 de l'Université de Würzburg.Il entreprend ensuite un travail de doctorat au Max-Planck Institut für Biophysikalische Chemie de Göttingen, et obtient en 1978 le grade de docteur ès sciences de l'Université de Göttingen. De 1978 à 1983 il effectue des recherches au Max-Planck Institut für Biologie à Tübingen et en 1984, il rejoint le Biocentre à Bâle où il travaille jusqu'en 1989, effectuant une année au Karolinska Institute à Stockholm. En 1989, Horst Vogel rejoint l'institut de chimie physique de l'EPFL où il dirige un groupe travaillant dans les domaines de la biophysique et de la bioélectronique.
Depuis le 1er octobre 1994 il est profeseur en chimie physique des polymères et membranes au Département de chimie de EPFL. Ses intérêts de recherche sont l'étude de la structure et de la dynamique de récepteurs membranaires et l'auto-assemblage des biomolécules aux interfaces pour développer de nouveaux biocapteurs dans le domaine de micro- et nanotechnologie. Il enseigne les sciences du vivant, la biophysique et biochimie, et des chapitres concernant la biotechnologie.
Dipl. in Chemistry1974-Univ. Würzburg, DE
Ph.D.-1978-MPI für Biophys. Chemie, Göttingen, DE
Li Tang
Education and Training Postdoctoral Fellow, Massachusetts Institute of Technology, 2013 - 2016 Ph.D., University of Illinois at Urbana-Champaign, 2007 - 2012 B.S., Peking University, 2003-2007
Michel Aguet
Dr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Jacques Fellay
Jacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
Stewart Cole
Professor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.